Skip to main content
. 2020 Jan 30;12:703–717. doi: 10.2147/CMAR.S225376

Figure 9.

Figure 9

EGFR and STAT3 affect tumor growth through JAK/STAT3 signaling. (A–D) CCK8 assay, colony formation and wound healing assays showed that the JAK/STAT3 inhibitor Ruxolitinib could suppress tumor cell proliferation and invasion. **P<0.01.